LNTH Lantheus Holdings Inc

Lantheus to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

Lantheus to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

BEDFORD, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Brian Markison, Chief Executive Officer, will present at the Morgan Stanley 23rd Annual Global Healthcare Conference at 7:00 a.m. ET on Tuesday, September 9.

To access the live webcast of the presentation, please visit the Investors section of the Company’s website at . A replay of the webcast will be available on the Company’s website for at least 30 days following the live presentation.

About Lantheus

Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Sweden and Switzerland, Lantheus has been providing radiopharmaceutical solutions for nearly 70 years. For more information, visit .

Contacts:

Mark Kinarney

Vice President, Investor Relations

978-671-8842

Melissa Downs

Executive Director, External Communications

646-975-2533



EN
02/09/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Lantheus Holdings Inc

 PRESS RELEASE

Lantheus and GE HealthCare Announce Exclusive Licensing Agreement for ...

Lantheus and GE HealthCare Announce Exclusive Licensing Agreement for Prostate Cancer Imaging Agent PYLARIFY® (Piflufolastat F 18) in Japan BEDFORD, Mass. and CHICAGO and TOKYO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc.  (NASDAQ: LNTH) and GE HealthCare (NASDAQ: GEHC) today announced an exclusive licensing agreement for GE HealthCare to develop, manufacture, and commercialize Lantheus’ piflufolastat F18 (PYLARIFY® in U.S. market) in Japan for prostate cancer diagnostics and companion diagnostic use. PYLARIFY is used for positron emission tomography (PET) imaging of prosta...

 PRESS RELEASE

Lantheus to Present at the Morgan Stanley 23rd Annual Global Healthcar...

Lantheus to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference BEDFORD, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Brian Markison, Chief Executive Officer, will present at the Morgan Stanley 23rd Annual Global Healthcare Conference at 7:00 a.m. ET on Tuesday, September 9. To access the live webcast of the presentation, please visit the Investors secti...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

 PRESS RELEASE

Lantheus Reports Second Quarter 2025 Financial Results and Provides Bu...

Lantheus Reports Second Quarter 2025 Financial Results and Provides Business Update Recorded second quarter 2025 worldwide revenue of $378.0 million, GAAP fully diluted earnings per share of $1.12, adjusted fully diluted earnings per share of $1.57 and free cash flow of $79.1 millionAnnounced FDA acceptance of NDA for new formulation for piflufolastat F 18 PSMA PET imaging agent with a PDUFA date of March 6, 2026Closed acquisition of Life Molecular Imaging in July, immediately expanding near- and long-term growth profile and commercial portfolio with Neuraceq® (florbetaben F 18 injection), ...

 PRESS RELEASE

Lantheus Announces FDA Acceptance of NDA for New Formulation for Marke...

Lantheus Announces FDA Acceptance of NDA for New Formulation for Market-Leading PSMA PET Imaging Agent Designed to expand PSMA PET imaging access for patients by increasing batch size by ~50% and enhancing supply resiliencePDUFA date set for March 6, 2026 BEDFORD, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that the Food and Drug Administration (FDA) has accepted a New Dru...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch